FR3058143B1 - Nanocorps anti-tau - Google Patents

Nanocorps anti-tau Download PDF

Info

Publication number
FR3058143B1
FR3058143B1 FR1660450A FR1660450A FR3058143B1 FR 3058143 B1 FR3058143 B1 FR 3058143B1 FR 1660450 A FR1660450 A FR 1660450A FR 1660450 A FR1660450 A FR 1660450A FR 3058143 B1 FR3058143 B1 FR 3058143B1
Authority
FR
France
Prior art keywords
tau
nanocbodies
relates
present
nanobodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1660450A
Other languages
English (en)
French (fr)
Other versions
FR3058143A1 (fr
Inventor
Daniel Fagret
Marcelle Moulin
Catherine Ghezzi
Pascale Perret
Sabine Chierici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1660450A priority Critical patent/FR3058143B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Grenoble, Universite Grenoble Alpes filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to EP17798139.6A priority patent/EP3532495A1/fr
Priority to PCT/EP2017/077691 priority patent/WO2018078140A1/fr
Priority to US16/345,279 priority patent/US10590191B2/en
Priority to JP2019545850A priority patent/JP7197494B2/ja
Priority to CN201780080870.6A priority patent/CN110225926B/zh
Priority to CA3041066A priority patent/CA3041066A1/fr
Publication of FR3058143A1 publication Critical patent/FR3058143A1/fr
Application granted granted Critical
Publication of FR3058143B1 publication Critical patent/FR3058143B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR1660450A 2016-10-27 2016-10-27 Nanocorps anti-tau Active FR3058143B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1660450A FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau
PCT/EP2017/077691 WO2018078140A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau
US16/345,279 US10590191B2 (en) 2016-10-27 2017-10-27 Anti-tau nanobodies
JP2019545850A JP7197494B2 (ja) 2016-10-27 2017-10-27 抗Ｔａｕナノボディ
EP17798139.6A EP3532495A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau
CN201780080870.6A CN110225926B (zh) 2016-10-27 2017-10-27 抗Tau纳米抗体
CA3041066A CA3041066A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1660450A FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau
FR1660450 2016-10-27

Publications (2)

Publication Number Publication Date
FR3058143A1 FR3058143A1 (fr) 2018-05-04
FR3058143B1 true FR3058143B1 (fr) 2021-03-12

Family

ID=58314353

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1660450A Active FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau

Country Status (7)

Country Link
US (1) US10590191B2 (enExample)
EP (1) EP3532495A1 (enExample)
JP (1) JP7197494B2 (enExample)
CN (1) CN110225926B (enExample)
CA (1) CA3041066A1 (enExample)
FR (1) FR3058143B1 (enExample)
WO (1) WO2018078140A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
CN112649615A (zh) * 2020-12-21 2021-04-13 大连理工大学 一种检测不同大小的可溶性Aβ寡聚体的方法及应用
FR3134390B1 (fr) 2022-04-11 2025-10-24 Univ Grenoble Alpes Peptide utile pour le transport de molecules au travers de barrieres cellulaires

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU6248994A (en) 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
AU701643B2 (en) 1994-09-12 1999-02-04 Schering Aktiengesellschaft Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SMT201800109T1 (it) * 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
WO2014059442A2 (en) 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
HRP20201064T1 (hr) * 2013-06-10 2021-01-22 Ipierian, Inc. Postupci liječenja tauopatije
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

Also Published As

Publication number Publication date
CN110225926A (zh) 2019-09-10
FR3058143A1 (fr) 2018-05-04
US10590191B2 (en) 2020-03-17
JP2020505056A (ja) 2020-02-20
CA3041066A1 (fr) 2018-05-03
JP7197494B2 (ja) 2022-12-27
WO2018078140A1 (fr) 2018-05-03
CN110225926B (zh) 2024-05-03
US20190263898A1 (en) 2019-08-29
EP3532495A1 (fr) 2019-09-04

Similar Documents

Publication Publication Date Title
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
MX2018003696A (es) Composicion acida que comprende una ficocianina.
EA202092435A3 (ru) Моноклональные антитела против bcma
TR201905829T4 (tr) Buzdolabı.
CL2017001393S1 (es) Automovil
CL2017001185S1 (es) Automovil
EA201992177A1 (ru) Композиции на основе нирапариба
PH12016501763A1 (en) Multispecific antibodies
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
TR201908795T4 (tr) Bi̇r şeki̇llendi̇ri̇lebi̇li̇r kütleni̇n şeki̇llendi̇ri̇lmesi̇ i̇çi̇n ci̇haz
FR3058143B1 (fr) Nanocorps anti-tau
MX380240B (es) Preparación de piperidin-4-carbotioamida.
FR3044927B1 (fr) Emulsion magnetique reactive
MA44833A (fr) Nanoparticules extrêmement petites de polymères dégradables
TR201401768A2 (tr) Miyasteninin tedavisine yönelik bir kompozisyon.
TR201401766A2 (tr) Asteninin tedavisine yönelik bir kompozisyon.
UA114708U (uk) Тяговий привід електробуса
MX2017010899A (es) Proceso para la preparacion de triazoles.
GT201400051S (es) Escúter o motoneta
ECSDI15050234S (es) Motocicleta
MX2016016577A (es) Aleacion de fundicion de aluminio.
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية
ITMI20141626A1 (it) Metodo di disegno
ITMI20141625A1 (it) Metodo di disegno

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180504

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

TQ Partial transmission of property

Owner name: UNIVERSITE GRENOBLE ALPES, FR

Effective date: 20220620

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20220620

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE, FR

Effective date: 20220620

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10